Kobin, A. and Sheth, N. Levels of adherence required for virological suppression among newer antiretroviral medication. Ann Pharmacol. 2011;45(3):372-9.
Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010 Apr 15;50(8):1192-7.
Melikian GL, Rhee SY, Varghese V, et al. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother. 2014 Jan;69(1):12-20.
Gardner EM, Hullsiek KH, Telzak EE, et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS. 2010 Jan 28;24(3):395-403.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.
Byrd KK, Hou JG, Hazen R, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019 Nov 1;82(3):245-251.